Steve Elms - Dec 23, 2024 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Role
Director
Signature
/s/ Julio C. Esquivel, as Attorney-in-Fact for Steve Elms
Stock symbol
MRKR
Transactions as of
Dec 23, 2024
Transactions value $
$35,472
Form type
4
Date filed
12/26/2024, 04:01 PM
Previous filing
Dec 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRKR Common Stock Purchase $35.5K +11.1K +3.53% $3.20 325K Dec 23, 2024 See Footnote F1, F2, F3
holding MRKR Common Stock 2.97K Dec 23, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024.
F3 The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.